Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment beQuoted
GSK’s Jemperli wins EU nod for broader use in front-line endometrial cancer FirstWord Pharma
Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis …
Heterotaxia is characterized by an abnormal positioning of the thoracic and/or abdominal organs, resulting in various physiological and hemodynamic implications. Congenital heart disease involves structural irregularities in the heart or …
The dynamic nature of human endometrial tissue presents unique challenges in analysis. Despite extensive research into endometrial disorders such as endometriosis and infertility, recent systematic reviews have highlighted concerning issues …
What is the hormone receptor profile of adenomyosis lesions in comparison to correctly located endometrium?
This study aimed to assess the causal relationship between lipidome and female reproductive diseases (FRDs) using an advanced series of Mendelian randomization (MR) methods. This study utilized genome-wide association study …
Whether cyst size affects ovarian reserve before and after surgery remains controversial.
Cognitive complaints are commonplace among women living with endometriosis-associated chronic pelvic pain (CPP); yet, surprisingly few studies have assessed their cognitive functioning. As an initial step to address the resulting …